Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). John D. Fowler, Jr. appointed Class II director effective March 1, 2026; independent under NYSE standards, joining Audit and Finance Committee.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- John D. Fowler, Jr. appointed Class II director effective March 1, 2026; independent under NYSE standards, joining Audit and Finance Committee
- Initial RSU grant valued at $270,000, vesting in 3 equal annual installments over 3 years
- Annual compensation: $70,000 cash retainer + $15,000 Audit Committee retainer + $270,000 equity award (75% RSUs / 25% options)
- No related-party conflicts disclosed; appointment not tied to any third-party arrangement
Item 7.01 · Regulation FD Disclosure
- Press release issued March 3, 2026 announcing appointment of Mr. Fowler, furnished as Exhibit 99.1
- Reg FD disclosure signals leadership change deemed material enough for broad investor communication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.